drugset / Trial / NCT06792214
Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical Trial
Phase 4
Recruiting
118 enrolled
Mount Sinai Hospital, Canada
Kingston Health Sciences Centre · collabNiagara Health System · collabUnity Health Toronto · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The DEFEND trial will be the world's first clinical trial to study the effectiveness of Paxlovid or Veklury in the prevention of cardiovascular post-acute sequelae of SARS-CoV-2 among hospitalized adults. Additionally, this pilot study will inform the design and conduct of a future full-scale multi-centre trial by testing the feasibility and accuracy of this study design.
Timeline
- Start
- 2025-01-03
- Primary completion
- 2026-01
- Completion
- 2027-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nirmatrelvir/ritonavir | Unknown | — | Oral |
| Subject | Remdesivir | Small molecule | — | Intravenous |